Factory High Quality Dalbavancin CAS 171500-79-1

• Customization: Available
• CAS No.: 171500-79-1
• Formula: C88h100cl2n10o28
• Model NO.: 171500-79-1
• EINECS: 206-141-6
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Industrial
• Colour: White
• Transport Package: as Demanded
• Specification: CP, USP, EP
• Trademark: Worldyang
• Origin: China
• HS Code: 3808929090
• Production Capacity: 1000kg/Year

Product Description

Shanghai Worldyang chemical Co., Ltd is a high-tech enterprise focused on industry of fine chemicals research and develop, produce and sale. Shanghai Worldyang chemical Co., Ltd is located in Shanghai China. we have the ability to provide you high quality products. More than 90 % of our products are exported to developed countries and regions such as north America, Europe, Japan, South Korea and the Middle East.

Products are widely used in pesticides, plastics, cosmetics, spices fragrance, water treatment, environmental protection, electronic chemicals and other fields. Up to now, we have established manufacturing bases in Anhui, jiangsu and guangdong separately, at the same time, we build closely cooperative relationship with the well-known universities and institutions of China to research new products constantly.

In addition, we also provide customized services for chemicals and organ silicon for customers around the world. Up the tonnage level down to the gram level can be provided to meet the different needs of our customers. We are good at a variety of reactions, including halogen exchange fluorination, halogenation, nitration, diazotization, grignard and reduction.
 

Oritavancin (Orbactiv)
CAS: 171500-79-1
Appearance: White powder
Certification: ISO 9001:2015; GMP
Specification: USP-40, ≥98%

Overview

Dalbavancin, also known as dauricin, is a novel semi synthetic glycopeptide antibiotic derived from the analogue A40926 of teicoplanin. It was discovered, developed, and entered clinical trials by Vicuron Pharmaceuticals in the United States, and later acquired by Pfizer. Dabwanxing has the same mechanism of action as vancomycin and teicoplanin, inhibiting the biosynthesis of G+bacterial cell walls and is widely used as a drug for treating skin and soft tissue infections. In vitro and in vivo experiments have shown that Dabawanxing has antibacterial activity against G+bacteria, including methicillin-resistant Staphylococcus aureus (MRSAC Chemicalbook), methicillin-resistant Staphylococcus aureus (MSSA), coagulase negative Staphylococcus aureus (CoNS), streptococcus, etc. It is active against G+resistant pathogens including penicillin resistant and ceftriaxone resistant Streptococcus pneumoniae, teicoplanin insensitive CoNS, and non vanA enterococci; It also has activity against G+anaerobic bacteria. Dabawanxing has unique pharmacokinetic properties and can be administered at weekly intervals. At present, Dabawanxing has achieved good results in the treatment of catheter-related blood borne infections as well as skin and soft tissue infections. It has excellent in vivo antibacterial activity and safety, and is an ideal second-generation glycopeptide antibiotic.

Applications

It is a lipopeptide antibiotic with bactericidal activity against Gram positive bacteria such as various Staphylococcus aureus.

Research and Development

Our research team used synthetic biotechnology to reconstruct the synthetic biological system of the precursor A40926 producing strain of Dabawanxin, and obtained high-yield strains. After synthesizing precursor A40926, Dabawanxin was obtained through three steps of chemical modification (R3 amidation), with a dry content of ≥ 98% and almost no impurities of homologous substances in the raw material. The project has been granted a Chinese invention patent and has independent intellectual property rights.

Name	Dalbavancin
CAS Number	171500-79-1
Standard	CP, USP, EP
Package	1kg/drum, 25kg/drum and as demanded